Amyloidosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
*The [[incidence]] of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.<ref name="pmid116772762">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref> | *The [[incidence]] of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.<ref name="pmid116772762">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref> | ||
*The [[incidence]] of AL amyloidosis in USA ranged from 1 per 100,000 to 1.4 per 100,000 from 2007 to 2015.<ref name="pmid29748430">{{cite journal |vauthors=Quock TP, Yan T, Chang E, Guthrie S, Broder MS |title=Epidemiology of AL amyloidosis: a real-world study using US claims data |journal=Blood Adv |volume=2 |issue=10 |pages=1046–1053 |date=May 2018 |pmid=29748430 |pmc=5965052 |doi=10.1182/bloodadvances.2018016402 |url=}}</ref> | *The [[incidence]] of AL amyloidosis in USA ranged from 1 per 100,000 to 1.4 per 100,000 from 2007 to 2015.<ref name="pmid29748430">{{cite journal |vauthors=Quock TP, Yan T, Chang E, Guthrie S, Broder MS |title=Epidemiology of AL amyloidosis: a real-world study using US claims data |journal=Blood Adv |volume=2 |issue=10 |pages=1046–1053 |date=May 2018 |pmid=29748430 |pmc=5965052 |doi=10.1182/bloodadvances.2018016402 |url=}}</ref> | ||
*Transthyretin-related hereditary amyloidosis is endemic in Portuguese locations Póvoa de Varzim and Vila do Conde (Caxinas), with more than 1000 affected people, coming from about 500 families, where 70% of the people develop the illness. In northern Sweden, more specifically Piteå, Skellefteå and Umeå, 1.5% of the population has the mutated gene. There are many other populations in the world who exhibit the illness after having developed it independently. | |||
===Prevalence=== | ===Prevalence=== | ||
Latest revision as of 18:38, 29 October 2019
|
Amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Amyloidosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Amyloidosis epidemiology and demographics |
|
Risk calculators and risk factors for Amyloidosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide. The prevalence of AL amyloidosis increased significantly between 2007 and 2015, from 1.6 per 100,000 in 2007 to 4.0 per 100,000 in 2015. The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries. In amyloidosis, the mean age of presentation is 55 - 60 years. Men are more commonly affected by amyloidosis than women.
Epidemiology and Demographics
Incidence
- The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.[1]
- The incidence of AL amyloidosis in USA ranged from 1 per 100,000 to 1.4 per 100,000 from 2007 to 2015.[2]
- Transthyretin-related hereditary amyloidosis is endemic in Portuguese locations Póvoa de Varzim and Vila do Conde (Caxinas), with more than 1000 affected people, coming from about 500 families, where 70% of the people develop the illness. In northern Sweden, more specifically Piteå, Skellefteå and Umeå, 1.5% of the population has the mutated gene. There are many other populations in the world who exhibit the illness after having developed it independently.
Prevalence
- The prevalence of AL in USA amyloidosis increased significantly between 2007 and 2015, from 1.6 per 100,000 in 2007 to 4.0 per 100,000 in 2015.[3]
Mortality rate
- The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.[4]
Age
Race
- Hereditary amyloidosis subtypes include a substitution of an amino acid that is detected in approximately 4% of the black population.[6]
Gender
- Men are more commonly affected by amyloidosis than women.[7]
References
- ↑ Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
- ↑ Quock TP, Yan T, Chang E, Guthrie S, Broder MS (May 2018). "Epidemiology of AL amyloidosis: a real-world study using US claims data". Blood Adv. 2 (10): 1046–1053. doi:10.1182/bloodadvances.2018016402. PMC 5965052. PMID 29748430.
- ↑ Quock TP, Yan T, Chang E, Guthrie S, Broder MS (May 2018). "Epidemiology of AL amyloidosis: a real-world study using US claims data". Blood Adv. 2 (10): 1046–1053. doi:10.1182/bloodadvances.2018016402. PMC 5965052. PMID 29748430.
- ↑ Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
- ↑ Shin YM (March 2011). "Hepatic amyloidosis". Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.
- ↑ Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
- ↑ Shin YM (March 2011). "Hepatic amyloidosis". Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.